13:49 ET -- Johnson & Johnson is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The company agreed to buy heart-pump maker Abiomed Inc. in an all-cash deal valued at $16.6 billion upfront, including cash. J&J agreed to pay $380 a share upfront, and would pay an additional $35 a share if certain milestones are met. Abiomed shares were recently up 50% to $378.85. J&J shares declined less than 1% to $172.99. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)

(END) Dow Jones Newswires

November 01, 2022 14:04 ET (18:04 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Johnson and Johnson Charts.